Explore more publications!
Harrisburg Wellness Reporter
Got News to Share?

Harrisburg Wellness Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 24, 2025

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
November 24, 2025

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Indeterminate GlobeNewswire
Biotech Valuations Rise as New Clinical Platforms Show Progress
November 24, 2025

Biotech Valuations Rise as New Clinical Platforms Show Progress

Indeterminate GlobeNewswire
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
November 24, 2025

Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

Indeterminate GlobeNewswire
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
November 24, 2025

Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Indeterminate GlobeNewswire
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
November 24, 2025

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Indeterminate GlobeNewswire
Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting
November 24, 2025

Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
November 24, 2025

Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

Indeterminate GlobeNewswire
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
November 24, 2025

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Indeterminate GlobeNewswire
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
November 24, 2025

Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals

Indeterminate GlobeNewswire
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
November 24, 2025

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Indeterminate GlobeNewswire
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025

LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference

Indeterminate GlobeNewswire
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
November 24, 2025

Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting

Indeterminate GlobeNewswire
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025

Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Indeterminate GlobeNewswire
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
November 24, 2025

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Indeterminate GlobeNewswire
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
November 24, 2025

Daré Bioscience Receives $3.6 Million in Additional Grant Funding

Indeterminate GlobeNewswire
HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing
November 24, 2025

HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing

Indeterminate GlobeNewswire
Iterum Therapeutics Provides Business Update
November 24, 2025

Iterum Therapeutics Provides Business Update

Indeterminate GlobeNewswire
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
November 24, 2025

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Indeterminate GlobeNewswire
Annovis Announces Two Presentations at the CTAD 2025 Conference
November 24, 2025

Annovis Announces Two Presentations at the CTAD 2025 Conference

Indeterminate GlobeNewswire
ProMIS Neurosciences Announces Reverse Stock Split
November 24, 2025

ProMIS Neurosciences Announces Reverse Stock Split

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions